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Concomitant PTEN loss of function mutations occur in 40% of BRAF-mutant 
melanomas. The introduction of BRAF/ MEK combination therapy has provided clinical 
benefit but the responses are transient. There is an urgent need to design rational 
combination therapies that could either be used as second line treatment to overcome 
resistance to BRAF/ MEK inhibition or as primary therapies leading to more durable 
responses. Using CRISPR we generated PTEN knockout clonal cell lines to interrogate 
the effects of PTEN loss on drug response and resistance. Consistent with clinical 
observations, we found that PTEN loss decreased sensitivity to growth inhibition by 
combined BRAF/MEK inhibition. In an effort to identify therapeutically targetable 
pathways and delineate the factors driving adaptive resistance to BRAF/MEK inhibition, 
we performed RNA sequencing and drug synergy screens. RNA sequencing revealed 
upregulation of the kinase ERBB3/HER3 and its transcriptional activator FOXD3 in the 
PTEN knock out cell lines, both of which have been shown to contribute to resistance to 
BRAF inhibitor monotherapy. Utilizing the PTEN knockout cell lines we employed drug 
screening technology using a compound library enriched for epigenetic modifiers and 
kinase inhibitors. Screening identified two EGFR/HER2 inhibitors, Afatinib and Neratinib 
that restored the sensitivity of PTEN knockout cells to BRAFi/MEKi treatment. Here we 
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show inhibition of HER2-mediated activation of HER3 with Neratinib restored the growth 
inhibitory effect of BRAFi/MEKi treatment on PTEN KO cells, suggesting that co-
targeting both BRAF and MEK with HER family inhibition holds promise for the 
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This thesis covers two main areas of research: melanoma and the effect of PTEN 
loss on adaptive resistance. The first part of the introduction gives an overview of the 
origins of melanoma and its current therapeutic modalities, specifically focusing on 
resistance mechanisms to targeted therapy. The second part introduces adaptive HER3 
signaling, which I identified, as a promising targetable node to overcome resistance to 
targeted therapy in PTEN-deficient melanomas. The third part concludes with future 
directions aimed at dissecting the role of PTEN loss in resistance to long-term treatment 
and how to rationally design therapeutics to combat this resistance. 
1.1 Origin of melanoma 
Melanocytes are generated from the neural crest population during embryogenesis 
(Douarin et al., 2004). During early embryonic development neurulation occurs. 
Neurulation is the folding process of the neural plate into the neural tube by which a 
group of cells derived from the edges of the neural plate undergo an epithelial to 
mesenchymal transition. These cells are termed neural crest cells (NCCs). NCCs 
become migratory directly after formation and those that migrate dorsolaterally into the 
ectoderm become melanocytes (Sommer, 2011).  
Melanoma arises when melanocytes, the pigment-producing cells within the skin 
that protect skin cells from UV-induced DNA damage, undergo malignant transformation 
and aberrantly proliferate to generate a tumor cell mass. Melanocytes are dendritic cells 
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and represent the second largest cell population within the skin after keratinocytes. 
They are located in the dermis and the basal layer of the epidermis (Yaar and Gilchrest, 
2001). UV-induced DNA damage is the main carcinogen associated with the 
development of melanoma (D’Orazio et al., 2013). UV irradiation induces DNA damage 
by causing T-T dimers within DNA which can induce genetic mutations leading to 
aberrant cell growth and survival (Boyle, 2008). Melanocytes protect skin cells from UV-
mediated damage by producing the pigment melanin in specialized organelles called 
melanosomes, which is secreted to adjacent keratinocytes (Carsberg et al., 1994). 
When melanin is secreted to the keratinocyte, the pigment accumulates around the 
nucleus building a photo-protective barrier against UV irradiation (Brenner and Hearing, 
2008).  
Molecularly, melanocytes are characterized by the expression of genes such as: 
tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), as well as the microphthalmia 
transcription factor (MITF) (Lee et al., 2013). TYR and TYRP1 encode enzymes acting 
in the melanin synthesis pathway and MITF is crucial for melanoblast proliferation 
(Cichorek et al., 2013; Hou and Pavan, 2008). Whole transcriptome analysis has also 
revealed melanocytes express a set of cell cycle regulated genes involved in cell 
division such as CDC20, which may explain their high risk of developing into 
melanomas (Reemann et al., 2014). 
1.2 Incidence and mortality 
 
Melanoma is the most aggressive form of skin cancer, but when detected early can 
be treated with surgery, which leads to ~91% cure rates. Unresectable melanoma is 
marked by resistance to chemotherapy and ultimately leads to rapid metastasis. The 
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National Cancer Institute estimated 178,560 new cases of melanoma were diagnosed in 
the United States in 2018. Of those, 91,270 cases were unresectable, resulting in an 
estimated (9,320) 5,990 and 3,330 deaths for men and women respectively (“Melanoma 
of the Skin - Cancer Stat Facts,” n.d.; Street, 1930). Over the course of 2008 – 2018 the 
number of new melanoma cases diagnosed annually has increased by 53 percent 
(“Cancer Facts & Figures - 2008,” 1930; Street, 1930). 
Epidemiologic and molecular data have linked all forms of skin cancer to UV 
exposure (Linos et al., 2009). It is estimated that 65% of all melanoma cases in the US 
can be attributed to UV radiation from sun exposure (Armstrong and Kricker, 1993). In 
the UK, UV exposure is causative for nearly 86% of melanoma cases (Armstrong and 
Kricker, 1993; Parkin et al., 2011).  Despite increasing knowledge about melanoma and 
risk factors for this disease, incidence and mortality continue to rise partly due to the 
increase in popularity of indoor tanning (Lazovich et al., 2016).  Although melanoma 
only accounts for 2% of all skin cancers, it is responsible for the vast majority of skin 
cancer related deaths. This can be attributed to the aggressiveness of this disease and 
highlights the need for improved treatment modalities.  
1.3 Common mutations in melanoma 
While exposure to UV radiation is the largest risk factor in developing melanoma, 
molecular aberrations that drive the malignant transformation of melanocytes can also 
increase one’s risk of developing melanoma. The mitogen-activated protein kinase 
(MAPK) pathway is involved in cell proliferation and survival and mutations in this 
intracellular signaling pathway have been linked to melanoma (Cargnello and Roux, 
2011; Dhillon et al., 2007). The MAPK pathway is activated upon ligand binding to a 
receptor tyrosine kinase (RTK) and leads to subsequent phosphorylation of 
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RAS/RAF/MEK/ERK (MAPK family members) as depicted in detail in Figure 1A. 
Approximately 50% of all melanomas harbor a mutation in the oncogene BRAF. The 
BRAFV600E mutation is the most commonly identified mutation in the clinic (Ascierto et 
al., 2012). When BRAF is inactive, the conserved aspartate (D), phenylalanine (F), and 
glycine (G) or DFG motif found in the activation loop is flipped so that it is oriented 
toward the P-loop causing the residues required for phosphotransfer reactions to align 
but the ATP and peptide substrate recognition segments are partially disorganized. 
V600 is located in the activation loop close to the DFG motif. The BRAFV600E mutation 
results in an amino acid substitution of valine to glutamic acid at residue 600. During 
this substitution, the inactive orientation of the DFG motif is destabilized because 
BRAF’s kinase activation loop (residues 596-600) does not bind to inhibit the P-loop 
(residues 464-471), which restores the activation loop to an active conformation and 
ultimately renders BRAF constitutively active. BRAFV600E has been shown to be ~500 
fold more active than wild type BRAF (Wan et al., 2004).  
1.4 PTEN loss in melanoma 
 
In addition to mutations occurring in the MAPK pathway, other genes are 
mutated in melanomas such as PTEN (phosphate and tensin homologue deleted on 
chromosome ten). PTEN is the second most commonly mutated tumor suppressor in 
cancers, second only to p53, and is altered in various cancer types including 
glioblastomas, endometrial, breast, thyroid and prostate cancers (Li et al., 1997; Steck 
et al., 1997). Loss of PTEN is causative in autosomal dominantly inherited Cowden 
syndrome, a disease characterized by harmartomatous polyps that can occur in any 
organ, developmental defects, and increased risk of malignant tumors in the thyroid, 
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endometrium, or breast (Blumenthal and Dennis, 2008).  Not only is PTEN a tumor 
suppressor, it is also a lipid phosphatase and acts as a negative regulator of PI3K 
signaling by dephosphorylating PIP3 (phosphatidylinositol 4,5 tri-phosphate) to produce 
PIP2 (phosphatidylinositol 4,5 bi-phosphate). This dephosphorylation event ultimately 
prevents AKT activation and subsequent regulation of growth, survival, and apoptosis 
(Maehama and Dixon, 1998).  Loss of function mutations within the tumor suppressor 
PTEN occurs in 40% of sporadic melanomas and in up to 70% of melanoma cell lines 
(Guldberg et al., 1997; Stahl et al., 2003). The importance of PTEN loss in 
melanomagenesis has been supported by studies showing that a BRAF mutation in 
cooperation with PTEN loss facilitates tumor formation and metastasis to distal organs 
in a mouse model, suppresses BIM mediated apoptosis of melanoma cells treated with 
a BRAF inhibitor, and induces activation of AKT leading to resistance in pre-clinical 
models (Figure 1B) (Dankort et al., 2009; Paraiso et al., 2011; Shi et al., 2014). In the 
clinic, patients with PTEN loss experience shorter progression-free survival when 
treated with a BRAF inhibitor (Bucheit et al., 2014). Sporadic melanomas frequently 
have loss of PTEN via deletion or mutational inactivation but PTEN can also be 
epigenetically silenced by hypermethylation of the PTEN promoter (Zhou et al., 2000). 
PTEN methylation has been correlated to decreased patient survival in melanoma 
(Lahtz et al., 2010). Although these studies implicate PTEN loss as a critical event in 
melanoma tumorigenesis, effective treatment options for patients with PTEN-deficient 
BRAF-mutant melanomas remain elusive. 
1.5 Treatment strategies 
There are a number of treatment options for patients with melanoma, and 
specific options depend on the stage of the disease at diagnosis (Table 1.1). If 
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diagnosed early, surgical resection of a melanoma can prevent tumor spread and has a 
91% success rate. Beyond surgical removal, radiation is a common strategy to halt 
disease progression. Although radiation decreases tumor size, it does not prolong life 
expectancy and many patients experience undesirable side effects (Stevens et al., 
2000).  
Prior to 2011, the chemotherapeutic agent Dacarbazine was the mainstay of 
treatment for patients with unresectable metastatic melanoma (Chapman et al., 1999). 
Mapping of aberrant signaling pathways that promote growth and survival have defined 
specific kinases for therapeutic targeting in unresectable melanoma. In 2011, 
Vemurafenib became the first FDA approved targeted therapy for BRAF-mutant 
melanoma patients. Vemurafenib is a reversible, ATP-competitive inhibitor that binds to 
the kinase domain of BRAF ultimately inhibiting BRAF-induced MEK activation. Results 
from a randomized study comparing the chemotherapeutic agent Dacarbazine with 
Vemurafenib in previously untreated melanoma harboring V600E mutations 
demonstrated improved in progression- free survival from 1.6 months to 5.3 months. It 
was also shown to improve median overall survival (13.6 versus 9.7 months). Although 
Vemurafenib improved progression-free survival, patients experienced severe adverse 
events including the development of cutaneous squamous cell carcinoma (Chapman et 
al., 2011). Following Vemurafenib, another BRAF inhibitor (BRAFi), Dabrafenib, was 
FDA approved in 2013. Similar to Vemurafenib, Dabrafenib was tested in a randomized 
trial comparing the BRAFi to the chemotherapeutic Dacarbazine in BRAFV600E 
melanoma patients and demonstrated an improvement in median progression- free 
survival from 2.7 months to 6.9 months (Hauschild et al., 2012).  
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In addition to targeting BRAF, efforts have been made to target MEK signaling 
downstream of BRAF through the use of Trametinib, a small molecule inhibitor of 
MEK1/2. Trametinib was also FDA approved in 2013 for treatment of BRAFV600E or 
V600K mutant melanoma. Efficacy studies were performed in a randomized phase III 
trial comparing Trametinib to Dacarbazine. Similar to BRAFi trials, Trametinib increased 
overall survival from 67% to 81% without causing the adverse cutaneous events 
reported in Vemurafenib trials (Flaherty et al., 2012).  
Due to the emergence of resistance to monotherapy and reactivation of the 
MAPK pathway through sustained ERK signaling, combinatorial trials using Dabrafenib 
and Trametinib were undertaken. Combination therapy improved median OS survival to 
33.6 months at 3-year follow-up as well as increased tumor regression. The success of 
the combination trials led to the FDA approval of combination treatments in 2014 and 
the current standard of care is combining BRAF and MEK inhibition (Georgina V. Long 
et al., 2017). Recently, the FDA approved a new combination regimen of the BRAFi 
Encorafenib and the MEK inhibitor (MEKi) Binimetinib (Dummer et al., 2018).  
Immunotherapy is a newer treatment strategy that is growing in popularity. 
Immunotherapy involves disrupting the crosstalk between T cells and their environment 
via antibody directed inhibition of immunosuppression. Current immunomodulating 
treatments are anti-CTLA-4 and anti PD-1 antibodies. The improvements of progression 
free survival, tumor shrinkage, and overall survival connected with those treatments 
have been confirmed in phase III trials (Robert et al., 2015; Schadendorf et al., 2015). 
Despite the advances made in targeted therapeutics for patients with late stage 
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melanoma, chemotherapy remains a treatment option for prolonged survival but it is not 
desirable due to numerous side effects.  
1.6 Therapeutic challenges- resistance  
The FDA approval of combined BRAF and MEK inhibition and immunotherapy for 
BRAF-mutant metastatic melanoma has dramatically improved overall survival and 
demonstrated enhanced efficacy when compared to monotherapy. However, resistance 
to treatment and subsequent recurrence of disease remains a major clinical challenge. 
In contrast to intrinsic resistance, which is characterized by initial failure to respond to 
therapy, acquired resistance is marked by a positive response to treatment that is often 
overcome and eventually results in disease progression. The emergence of acquired 
resistance is frequently due to the adaptive tumor responses to BRAF and/or MEK 
inhibition. Adaptive responses to targeted kinase inhibition involve disruptions in 
signaling feedback and feedforward loops. Disease progression is observed as these 
changes can affect the expression of numerous protein kinases and lead to dramatic 
epigenetic and transcriptional changes within the tumor cell population ultimately driving 
therapeutic bypass of BRAF and/or MEK inhibition. Molecular mechanisms of acquired 
resistance to targeted therapy in melanoma have been identified and are depicted in 
Figure 1.2. Common effectors of resistance include amplification of mutant BRAF, 
dimerization of alternatively spliced BRAF, MEK1/2 and NRAS mutations, and 
overexpression of COT that promote the reactivation of the MAPK pathway (Emery et 
al., 2009; Johannessen et al., 2010; Nazarian et al., 2010; Poulikakos et al., 2011; Shi 
et al., 2012). Activation of compensatory survival pathways such as PI3K/AKT pathway 
via mutations in AKT1/AKT3, PIK3CA, NF1, and loss of function PTEN mutations have 
also been demonstrated in BRAFi and BRAFi/MEKi resistance (Irvine et al., 2018; 
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Paraiso et al., 2011; Shi et al., 2014; Whittaker et al., 2013). PTEN loss has also been 
shown to mediate resistance to immunotherapy by inhibiting T cell-mediated tumor 
killing (Peng et al., 2016).  Another major contributor to BRAFi and BRAFi/MEKi 
resistance in melanoma is the resultant upregulation/activation of RTKs including 
EGFR, PDGFRb, and MET (Nazarian et al., 2010; Shi et al., 2012).  
1.7 Identifying adaptive responses that promote resistance 
There is an intense effort to better understanding factors influencing resistance and 
develop novel treatment strategies that lead to more durable responses in patients. Our 
laboratory and others have demonstrated that adaptive responses to kinase inhibition 
can be in observed cell lines, animal models, and patient populations at very early time 
points following treatment (Brighton et al., 2018; Stuhlmiller et al., 2015; Zawistowski et 
al., 2017). Multiplexed Inhibitor Beads coupled with Mass Spectrometry (MIB/MS) is a 
chemical proteomics approach previously developed in our lab that allows us to capture 
expressed protein kinases and quantify functional kinome dynamics in cell and tumor 
lysates in response to treatment with targeted kinase inhibitors (Duncan et al., 2012). 
Using this technology, we can identify kinase pathways that are deregulated in resistant 
tumors. MIB/MS allows quantitative interrogation of >275 kinases in a single mass 
spectrometry run that far exceeds other methods available to assess kinome dynamics 
and adaptive responses. The MIB/MS technique shown in Figure 1.3. is able to 
accurately capture and quantify ~89% of the expressed kinome by using combinations 
of specific inhibitors (Bisindolylmaleimide-X, Dasatinib, and UNC-21474) and broader 
pan-kinase inhibitors (Shokat, PP58, Purvalanol B, VI-16832, and CTx-0294885) (Daub 
et al., 2008). Delineating epigenetic modifiers and transcriptomic changes that 
contribute to resistance is also an active area of research in our laboratory.  In order to 
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provide effective treatment to patients with melanoma it is necessary to understand how 
the kinome and transcriptome adapt to circumvent drug action. For my thesis work 
detailed in Chapter 2, I have delineated adaptive signaling mediating BRAFi/MEKi 














 1.8 Figures 
 
Figure 1.1 Commonly deregulated pathways in melanoma.  
Activation of receptor tyrosine kinases (RTKs) elicits downstream signaling 
pathways outlined in this diagram, which play critical roles in cell proliferation or 
survival. A) Constitutive activation of the mitogen activated protein kinase (MAPK) 
pathway in melanocytes via BRAF mutation occurs in 50% of melanomas and leads 
to uncontrolled proliferation. B) PTEN loss occurs in 40% of melanomas to activate 
the PI3K/AKT pathway to promote survival. Concomitant loss of PTEN and BRAF 
mutations produce highly penetrant, metastatic melanomas in the clinic. Aberrant 
signaling in these two pathways are highly relevant to my thesis works and are 







Figure 1.2 Resistance mechanisms to BRAFi/MEKi in melanoma. 
Combined BRAF and MEK inhibition has dramatically improved overall survival. 
However, resistance to treatment remains a major clinical challenge. Common 
mediators of resistance include amplification of mutant BRAF, dimerization of 
alternatively spliced BRAF, MEK1/2 and NRAS mutations, and overexpression of 
COT that promote the reactivation of the MAPK pathway. Alternatively, mutations in 
AKT1/AKT3, PIK3CA, NF1, and loss of function PTEN mutations activate 
compensatory survival pathways such as PI3K/AKT pathway that lead to 







Figure 1.3 Chemical proteomics approach to identify adaptive kinase 
signaling.  Cell lysates are passed over sepharose beads that are covalently bound 
to kinase inhibitors. This enables the enrichment of active protein kinases from cell 
lysates based upon kinase functional activity, expression, and relative affinity for 
each kinase inhibitor.  After affinity capture of kinases is followed by LC-MS/MS to 
















Abbreviations: PFS- progression free survival, OS- overall survival 
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CHAPTER 2: HER2 INHIBITION RESTORES SENSITIVITY OF PTEN-DEFICIENT, 
BRAFV600E MELANOMA TO BRAF/ MEK INHIBITORS 
 
2.1 Introduction 
While the genetic subset of mutations that contribute to melanoma are 
heterogeneous, a significant fraction (~50%) of melanomas have an activating BRAF 
mutation (V600E), which results in constitutive activation of the mitogen activated 
protein kinase (MAPK) pathway. Aberrant MAPK signaling leads to uncontrolled cell 
proliferation(Ascierto et al., 2012). Targeting BRAF and/or its downstream targets, MEK 
1/2, elicits potent antiproliferative effects and is the current clinical standard of care 
(Georgina V. Long et al., 2017; G. V. Long et al., 2017; Spain et al., 2016). Although the 
combination of BRAF and MEK inhibitors showed initial promise in patients by 
extending progression free survival, the development of resistance to these therapies 
and subsequent recurrence of disease remains a major clinical challenge (Wagle et al., 
2014). Evaluation of factors influencing resistance identified loss of function mutations 
within the tumor suppressor PTEN (Phosphatase and Tensin Homolog on Chromosome 
Ten) occurs in 40% of sporadic melanomas and in up to 70% of melanoma cell lines 
(Guldberg et al., 1997; Stahl et al., 2003). Studies have shown that a BRAF mutation in 
cooperation with PTEN loss facilitates tumor formation and metastasis to distal organs 
in melanoma (Dankort et al., 2009). 
Concurrent PTEN deficiency and activating BRAF mutations result in activation 




to resistance to BRAFi (BRAF inhibitor) and combined BRAFi and MEKi (MEK inhibitor) 
therapy (Deng et al., 2012; Vredeveld et al., 2012). PI3K pathway activation via loss of 
PTEN suppresses BIM mediated apoptosis of melanoma cells treated with BRAFi and 
induces activation of AKT leading to resistance in pre-clinical models (Paraiso et al., 
2011; Shao and Aplin, 2010). In the clinic, patients with PTEN loss experience shorter 
progression-free survival on Dabrafenib (BRAFi) (Bucheit et al., 2014). Despite the 
frequency of PTEN mutations in aggressive melanoma, therapies to combat the 
inevitable emergence of resistance remain elusive. To improve clinical efficacy of 
targeted therapies against PTEN-deficient melanomas an understanding of factors 
mediating resistance to BRAFi/MEKi therapy must be undertaken.  
Herein, we investigated the adaptive response to PTEN loss on BRAFi/MEKi 
resistance using RNAseq and chemical proteomics methods to interrogate the 
functional kinome. We identified the receptor tyrosine kinase ERBB3/HER3 and 
forkhead box D3 (FOXD3) transcription factor are induced upon PTEN loss in 
BRAFV600E melanoma. FOXD3 upregulation leads to overexpression of HER3 and 
subsequent BRAFi resistance. The possibility of FOXD3-HER3 signaling axis 
functioning as an adaptive mediator of drug response to BRAF/MEK combination 
therapy led us to explore adaptive kinase activity following BRAF/MEK pathway 
inhibition in BRAFV600E, PTEN deficient melanomas. Proteomic analysis revealed 
functional HER3 and AKT1/AKT3 suggesting HER3-PI3K/AKT pathway activation. We 
performed dose-dependent drug synergy screens to define novel combinatorial 
strategies that block resistance to BRAFi/MEKi in PTEN-deficient melanoma. Of interest 
was the drug synergy observed between inhibitors targeting HER2/EGFR and BRAF 
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and MEK. Treatment of PTEN-deficient melanoma cells with BRAF/MEK combination 
and the HER2/EGFR inhibitor, Neratinib, attenuated growth when compared with either 
treatment alone. These results suggest that BRAF mutant, PTEN-deficient melanomas 
adaptively shift to a HER3-dependent pathway in response to BRAF/MEK inhibitors and 
that targeting this pathway in conjunction with BRAF/MEK inhibition may provide 
therapeutic benefit in the clinic. 
2.2 Results 
2.2.1 Characterization of PTEN loss phenotype in BRAFV600E melanoma  
Since PTEN loss is commonly seen in melanoma patients with concomitant 
BRAF mutations, PTEN deficient cell lines were generated in order to interrogate the 
effects of PTEN loss on therapeutic response and adaptive resistance to combined 
BRAF/ MEK inhibition. PTEN expression was knocked down with a shRNA in 
BRAFV600E mutant melanoma cell lines (A375 and SK-MEL181). Western blotting 
confirmed decreased PTEN expression in both the A375 and SKMEL-181 cell lines as 
well as increased phosphorylation of AKT, consistent with activation of the PI3K 
pathway (Figure 2.1A-B). Treatment of these cell lines with increasing concentrations of 
Dabrafenib (BRAFi) in combination with Trametinib (MEKi) showed a decrease in 
sensitivity to BRAFi/MEKi with PTEN loss (Figure 2.1C-D).  
2.2.2 PTEN loss with stable deletion via CRISPR 
To further interrogate the effects of PTEN loss, PTEN was stably deleted using 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) in the A375 cell 
line. Isogenic clones were isolated and their PTEN expression levels were examined via 
western blotting (Figure 2.2A). Two independent clones, PTEN knockout 5 and PTEN 
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knockout 11 (KO5 and KO11) were chosen for further validation because they displayed 
the most similar cell morphology and growth rates. Similar to observations made in the 
PTEN knockdown cells, PTEN knockout (PTEN KO) lead to an increase in 
phosphorylated AKT with no effects on ERK phosphorylation (Figure 2.2B). 
Immunofluorescence also confirms lack of PTEN expression in the PTEN KO cells and 
no significant morphological changes as a result of PTEN loss (Figure 2.2C). 
Alternatively, isogenic clones with detectable PTEN expression via western blot showed 
no increase in phosphorylated AKT compared to the parental cell line indicating that 
changes in AKT phosphorylation are a direct result of PTEN loss. Increased 
phosphorylation and activation of AKT is consistent with deregulation of the PI3K 
pathway by PTEN depletion and ultimately leads to increased growth and survival (Stahl 
et al., 2003). Therefore, growth and drug response as a result of PTEN loss were 
examined.  
2.2.3 PTEN loss decreases sensitivity of BRAFV600E melanoma to BRAFi/MEKi 
combination treatment  
Dose-response relationships of BRAF/ MEK inhibition in A375 parental, KO5, 
and KO11 cell lines were performed to determine changes in drug sensitivity following 
PTEN knockout. As previously observed in the PTEN knockdown cells, treatment of 
PTEN KO cells with increasing concentrations of BRAFi/MEKi therapy resulted in a 
decrease in sensitivity to growth inhibition in comparison to the parental cell line. The 
half maximum inhibitory concentration (IC50) was analyzed over multiple experiments to 
calculate the fold change in IC50 resulting from PTEN loss. PTEN loss caused a 6.5-fold 
and 10-fold increase in KO5 and KO11 IC50 versus the parental cell line (Figure 2.2D). 
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Analysis of isogenic clones with detectable PTEN expression showed similar dose-
response relationships of BRAF/ MEK inhibition relative to parental cell line 
(Supplemental Figure S2.1A). In an effort to revert this phenotype ideally PTEN 
expression would be reintroduced into these cell lines. However, re-expression of PTEN 
causes marked growth suppression in multiple cell lines in our hands (data not shown). 
Hence, we opted instead to perturb the PI3K-AKT pathway by a different mechanism to 
determine if we could elicit the same phenotype.  
Activation of the PI3K-AKT pathway by PTEN deletion or activating mutations in 
PI3K have been observed in melanomas. To determine if perturbations in PI3K would 
elicit the same drug response as PTEN loss in BRAFV600E melanoma, flag-tagged 
PI3K overexpressing (PI3K O/E) and PI3KH1047R mutant (PI3KH1047R) cells were 
generated. The H1047R mutation results in an amino acid substitution at position 1047 
in the kinase domain of PIK3CA leading to increased catalytic activity and enhanced 
downstream signaling (Bader et al., 2006). Analysis of dose-response relationships of 
BRAF/ MEK inhibition showed treatment of the PI3KH1047R cells with increasing 
concentrations of BRAFi and MEKi lead to a decrease in sensitivity to BRAFi/MEKi, 
similar to previous observations in the PTEN KO cell lines (Supplemental Figure S2.2A-
C).  
To further characterize the cellular phenotype in response to treatment, short and 
long-term growth assays were performed on the A375 parental and PTEN KO cell lines. 
Dose-response relationships were used to determine the dose of BRAFi/MEKi 
combination to achieve optimal growth inhibition in PTEN KO cells.  After 6 days, the 
BRAFi/MEKi combination was able to completely inhibit growth in the parental cell line 
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but complete inhibition was not achieved with PTEN knock out (Figure 2.2E). 
Clonogenic growth was also assayed. Cells were plated at a low density, grown in the 
presence of BRAFi/MEKi, and after 2 weeks stained using crystal violet. BRAFi/MEKi 
had no growth inhibitory effect on the PTEN KO cells as evident by the formation of 
sizeable colonies. Quantification of the crystal violet stain confirmed this observation as 
treatment with BRAFi/MEKi combination caused a significant reduction in absorbance in 
the parental but not in the PTEN KO cell lines (Figure 2.2F). Consistent with current 
treatment strategies in the clinic, we observed a partial response with BRAFi/MEKi 
combination treatment and eventually a bypass of growth inhibition in the PTEN KO 
cells. The lack of a durable response to BRAFi/MEKi combination therapy warrants 
investigation of novel treatment strategies for BRAFV600E, PTEN deficient melanomas.  
2.2.4 PTEN loss induces a phenotypic state change  
In an effort to understand the functional consequence of PTEN loss, changes in 
gene transcription were assessed with the hopes of identifying therapeutically targetable 
pathways to overcome BRAFi/MEKi resistance. A375 parental, KO5, and KO11 
replicates were subjected to RNA sequencing (RNAseq). Unsupervised hierarchical 
clustering of the parental and PTEN KO cell lines showed overall concordance of KO5 
and KO11’s transcriptional response to PTEN loss (Figure 2.3A). RNAseq revealed 450 
and 1175 genes were transcriptionally upregulated ³ two-fold in response to PTEN loss 
in KO5 and KO11 respectively. Instead of examining clonal differences transcriptionally 
upregulated genes common to KO5 and KO11 were analyzed. Based upon previous 
work in our lab, we know that changes in kinase expression and activity as well as gene 
expression changes governed by transcription factors (TFs) can lead to resistance to 
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targeted therapeutics (Stuhlmiller et al., 2015; Zawistowski et al., 2017).  KO5 and 
KO11 common genes (422) that were log2 fold differentially expressed in the PTEN KOs 
versus the parental cell line were annotated as kinases or transcription factors (Figure 
2.3B-C). Interestingly, the receptor tyrosine kinase ERBB3/HER3 had a notable change 
in significance and magnitude. HER3 upregulation and activation is a major contributor 
to PI3K inhibitor and HER2 inhibitor resistance in HER2+ breast cancer as well as 
resistance to BRAFi monotherapy in BRAF-mutant melanoma. The TF FOXD3 was also 
transcriptionally upregulated (Figure 2.3C). FOXD3 induces the transcription of HER3 
via direct binding to the HER3 enhancer region. FOXD3 also enhances HER3 activation 
through its ligand neuregulin 1β (NRG1) resulting in enhanced AKT phosphorylation. 
This signaling complex leads to reactivation of the MAPK pathway and ultimately 
resistance to BRAFi monotherapy.  
2.2.5 Identification of synergistic drug combinations with BRAFi and MEKi 
Because of the effect of PTEN loss on drug response and transcription, we 
sought to identify vulnerabilities that could be targeted to provide a durable response 
and inhibit melanoma growth. A drug synergy screen utilizing a 175 compound, small 
molecule library was used to identify novel inhibitors that could synergize with 
BRAFi/MEKi therapy. The compound library, enriched for inhibitors of epigenetic 
modifiers and protein kinases, was used in 6x6 dose response matrices to screen for 
synergy in combination with Dabrafenib and Trametinib in the PTEN KO cell lines 
(Figure 2.4A). Compounds in the library were selected based on indications of clinical 
success and when suitable FDA-approval (Table S1). Synergy was measured using the 
Bliss independence model (Bliss) (Figure 2.4B). Screening identified two EGFR/HER2 
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inhibitors, Afatinib and Neratinib, with synergistic Bliss scores in the PTEN KO cell line 
(Figure 2.4C). Afatinib and Neratinib are FDA-approved drugs for the treatment of non-
small cell lung cancer and HER2+ breast cancer respectively (Ben–Baruch et al., 2015; 
Ricciuti et al., 2018). HER2 is the preferred heterodimer partner of HER3, 
transcriptionally upregulated in PTEN KO cells, and this signaling complex activates 
PI3K/AKT and MAPK signaling pathways. Additional compounds were identified in our 
screening data set such as Ibrutinib (BTK inhibitor). In addition to irreversibly inhibiting 
BTK, Ibrutinib has been shown to have off-target effects. Ibrutinib can also act as a pan-
EGFR family inhibitor by blocking the activation of EGFR, HER2, HER3, and HER4 in 
HER2+ breast cancer (Chen et al., 2016; Wang et al., 2016). Analysis of BTK 
expression levels from the RNAseq data set revealed BTK was not expressed in the 
KO5 or KO11 cell lines. Therefore, the synergy associated with Ibrutinib in the PTEN 
KO cells is likely due to off-targeting of HER family members. Because of this, follow up 
experiments were conducted using top synergy hits that demonstrated higher selectivity 
for HER2 inhibition.  
2.2.6 BRAFi/MEKi combination treatment induces HER2/HER3 heterodimer gene 
expression and activation 
Adaptive responses to targeted therapeutics can alter cell signaling causing 
changes in gene expression and activation of kinases ultimately leading to therapeutic 
resistance. Therefore, we dissected transcriptional patterns of the expressed kinome 
and TFs as well as the functional kinome in response to BRAFi/ MEKi combination 
treatment. Differential expression analysis revealed 1120 and 1479 genes were 
transcriptionally upregulated ³ two-fold in response to 1-day BRAFi/ MEKi treatment in 
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KO5 and KO11 cells respectively. Of these upregulated genes, 939 were common 
between KO5 and KO11. An increase in commonly upregulated genes (1038) was 
observed in 7-day treatments (Figure 2.5A-B). KO5 and KO11 common genes were 
again annotated as kinases or transcription factors. Concordant with the PTEN KO 
RNAseq data, the kinase HER3 had a notable change in significance and magnitude as 
well as the TF FOXD3 following BRAFi/MEKi treatment. Additionally, the lineage 
transcription factor SOX10 was also identified with increased expression following 
BRAF/ MEK combination therapy (Figure 2.5C). SOX 10 activates the transcription of 
FOXD3 in BRAF-mutant melanoma cells. The SOX10-FOXD3-HER3 pathway has 
recently been shown to amplify pro-survival signaling leading to adaptive resistance to 
BRAF inhibition (Han et al., 2018). Because previous studies have shown that 
resistance to BRAFi monotherapy is mediated through transcriptional regulation of 
HER3 and HER2 inhibition was identified as a possible targetable node to circumvent 
the lack of durability of BRAF/MEK inhibition, the expression and activity of other HER 
family proteins was examined.   
The HER family consists of four members HER1 (EGFR)- HER4. RNAseq 
revealed an induction of HER2 and HER3 expression but not EGFR or HER4 (Figure 
2.5C-D). The heterodimer consisting of HER2, which lacks a ligand, and HER3, which is 
kinase impaired, is the most robust signaling complex of the HER family and drives 
proliferation in breast cancer (Holbro et al., 2003). Only induction of HER2 was 
observed indicating HER3 expression and signaling was being driven by heterodimer 
formation with HER2. Increased production of NRG1 and subsequent formation and 
activation of the HER2/HER3 heterodimer has been shown in thyroid cancers and 
 35 
 
melanomas (Abel et al., 2013; Chakrabarty et al., 2012). Induction of the ligand NRG1 
in the PTEN KO cells was observed after 7-day BRAFi/ MEKi treatment concordant with 
increased expression of HER2 and HER3. RNAseq expression levels were validated by 
western blotting. Consistent with RNAseq, BRAFi/MEKi time course showed an 
increase in total HER3 expression. Hyperphosphorylation of HER2 and HER3 was also 
observed in PTEN KO cells in comparison to the parental cell line (Figure 2.5E). 
Hyperphosphorylation of HER3 was also confirmed in the PI3K cells via western blotting 
(Supplemental Figure S2.2C).  
  Commonly upregulated genes were subjected to pathway analysis. Enrichr 
analysis showed enrichment for focal adhesion-PI3K-AKT-mTOR signaling pathway 
following 1-day BRAFi/MEKi treatment. In figure 2.2B we demonstrate PI3K-AKT 
activation in KO5 and KO11 cells. Pathway analysis of 7-day treatments identified a 
significant enrichment for extracellular matrix (ECM) organization and collagen 
degradation (Supplemental Figure S2.3A-B). Tumor cells adjacent to bundled collagen 
have been shown to be persistent in the presence of MEKi implicating ECM remodeling 
as a potential diagnostic marker for therapeutic resistance to MEK inhibition in a BRAF-
mutant melanoma mouse model (Brighton et al., 2018). 
In addition to analyzing the transcriptional response to therapy via RNAseq, 
MIB/MS, a chemical proteomics approach, was employed to enrich and quantify the 
functional kinome. Multiplexed inhibitor beads (MIBs), Sepharose beads that are 
covalently bound to kinase inhibitors, enables the enrichment of active protein kinases 
from cell lysates based upon kinase functional activity, expression, and relative affinity 
for each kinase inhibitor.  After affinity capture of kinases, LC-MS/MS was performed to 
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identify and quantify the captured kinome. Quantitative assessment of the proteomic 
data was used to define the kinome response to BRAF/MEK inhibition after 1- and 7-
days treatment. Decreased MIB binding was observed for the kinases MAP2K1 (MEK1), 
MAP2K2 (MEK2), and BRAF consistent with targeted inhibition by a BRAFi (Dabrafenib) 
and MEKi (Trametinib). HER3, AKT1, and AKT3 were enriched as functional protein 
kinases via binding to MIB-affinity columns in the PTEN KO cells relative to parental 
cells post- BRAFi/MEKi treatment (Figure 2.5F). Induced kinases were found by 
MIB/MS, demonstrating functional kinase expression increases in PTEN KO cells in 
response to BRAF/MEK inhibition and may mediate survival and thus adaptive 
resistance in BRAFV600E, PTEN deficient melanomas.    
2.2.7 HER2 inhibition synergizes with BRAFi/MEKi combination therapy 
Having established through RNA-seq and MIB/MS analysis that BRAF/MEK 
inhibitor–induced FOXD3-HER3-AKT adaptive signaling occurred in PTEN-deficient 
melanomas, we sought to examine the effect of synergistic hits in attenuating this 
adaptive response. Screening hits were validated using fresh compound in short and 
long-term growth assays. Dose-response relationships of BRAF/ MEK inhibition versus 
BRAF/ MEK plus HER2 inhibition in A375 parental, KO5, and KO11 cell lines was 
compared. PTEN KO cells were treated with increasing concentrations of BRAFi/MEKi 
and/or 100nM Neratinib for 96 hours and cell viability was assessed using CellTiter Glo. 
The addition of Neratinib restored sensitivity of PTEN KO cells to BRAF/MEK inhibition. 
The IC50 for BRAFi/ MEKi shifted from 5.1 nM to 1.9 nM and 13.6 nM to 4.9 nM in KO5 
and KO11 cells respectively (Figure 2.6A).  After 9 days, the BRAFi/MEKi plus Neratinib 
(triple combination) is able to inhibit growth in the PTEN KO cell lines similar to the 
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growth inhibitory effects observed in the parental cell line with BRAFi/MEKi alone 
(Figure 2.6B).  
In PTEN KO cells, cotreatment of BRAFi/MEKi + Neratinib resulted in a durable 
synergistic growth suppression in long-term (4-week) crystal violet colony formation 
assays (Figure 2.6C). Due to the complexities in delivering a triple drug combination in 
an animal model with favorable pharmacokinetic/ pharmacodynamic interactions, as 
well as low toxicity, triple combination drug treatments were tested in 3D spheroid 
models. Using CellTiter-Glo 3D reagent ATP levels were assayed after 7 days. Neratinib 
synergized with BRAFi/MEKi to diminish cell viability in KO5 and KO11 3D spheroids 
(Figure 2.6D). Neratinib also synergized with BRAFi/MEKi to diminish cell viability in 
PI3KH1047R spheroids treated for 7 days (Supplemental Figure S2.3D). This data 
suggests a role for HER2 inhibition in the achievement of durable drug responses in 
PTEN-deficient melanomas.  
2.3 Discussion 
Resistance to combination BRAF/MEK inhibition occurs in most patients with 
BRAF-mutant melanoma, and only 20% of patients on combination treatment remain 
progression free after 3 years (Schreuer et al., 2017). Genetic alterations that co-occur 
with BRAF mutations such as loss of function mutations in the tumor suppressor PTEN 
have been shown to confer resistance to BRAFi monotherapy (Catalanotti et al., 2017). 
The responsiveness of BRAF-mutant melanoma patients to BRAF and MEK inhibitors 
varies substantially. Adaptive responses to targeted therapeutics can alter cell signaling 
pathways causing changes in gene expression and activation of receptor tyrosine 
kinases ultimately leading to therapeutic resistance. In this study, we generated PTEN 
KO cells and used RNAseq, chemical proteomics, and drug synergy screening to 
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provide insight into adaptive resistance during BRAFi/MEKi treatment and to identify 
therapeutic modalities that prevent this process.  
 Consistent with pre-clinical and clinical observations, we show that loss of PTEN 
alters the dose-response relationship of dual BRAF/MEK inhibitors by shifting the IC50 
and rendering cells insensitive to these inhibitors. Loss of PTEN also activated the 
PI3K/AKT pathway in our cell system. Further characterization of the PTEN null 
phenotype via transcriptomic analysis revealed a significant induction of HER3 and 
FOXD3. Studies have shown that FOXD3 upregulation leads to overexpression of 
HER3 and subsequent resistance to BRAFi monotherapy. Evaluation of HER3 
expression in primary melanomas and metastases immunohistochemically identified 
elevated levels of HER3 expression as a prognostic marker for poor survival (Reschke 
et al., 2008). To this end, examination of the FOXD3-HER3 signaling axis as a mediator 
of BRAFi/ MEKi adaptive resistance was undertaken. Analysis of transcriptomic 
changes after acute BRAFi/ MEKi therapy showed heightened increases in FOXD3 and 
HER3 expression. In addition, the lineage transcription factor SOX10 was also identified 
with increased expression following BRAF/ MEK combination therapy. More recently, 
studies have shown that SOX 10 activates the transcription of FOXD3 in BRAF-mutant 
melanoma cells and SOX10-FOXD3-HER3 pro-survival signaling pathway mediates 
adaptive resistance to BRAFi (Han et al., 2018). Although the transcriptional changes 
identified in our PTEN-deficient phenotype have been demonstrated in BRAF-mutant 
melanomas with intact PTEN and in response to single agent BRAF inhibitors, here we 
have attempted to delineate the contributions of PTEN in the transcriptional response to 
combined BRAF/ MEK inhibition. Comparing significance and magnitude of 
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transcriptional changes in PTEN-deficient cell lines to a parental cell line with intact 
PTEN firmly establish a role for the FOXD3-HER3 signaling axis in adaptive responses, 
not only as marker of a PTEN-deficient cellular phenotype but in the mediation of 
resistance to BRAF/MEK-targeted therapy.  
In addition to changes in gene expression, resistance to targeted therapy can 
also occur via activation of compensatory receptor tyrosine kinases.  Comprehensive 
profiling of adaptive kinases revealed increased functional activity of HER3 as well as 
AKT1 and AKT3 in PTEN-deficient melanomas. Activation of AKT1 in concert with 
PTEN loss results in decreased tumor latency and the development of lung and brain 
metastases in BRAFV600E mouse models (Shi et al., 2014). Metastasis is a major 
cause of melanoma related mortality. The ability of tumor cells to undergo metastasis 
requires adhesion, proteolysis of extracellular matrix components (ECM), and migration. 
These processes ultimately lead to metastatic growth in distant organs. Collagen 
regulates ECM remodeling by collagen degradation and re-deposition to promote tumor 
growth and progression. After 7 days on BRAFi/MEKi collagen degradation pathways 
are enriched in the PTEN KO cells. We believe PTEN loss may also promote a more 
metastatic phenotype through upregulation of AKT1 to drive resistance to therapy and 
provides an interesting area for follow-up studies. Myristoylated AKT3 has also been 
shown to partially protect melanoma cells from BRAFi induced apoptosis (Shao and 
Aplin, 2010). The lack of a durable response of BRAFV600E, PTEN-deficient 
melanomas may be explained by activation of an AKT redundant survival pathway 
and/or a robust, HER3-dependent adaptive response. Our BRAFi/MEKi screens 
identified inhibitors of HER2 as synergistic drug combinations in PTEN KO cell lines that 
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could abrogate this adaptive response. Neratinib and Afatinib are FDA-approved 
HER2/EGFR inhibitors and there are multiple clinical trials currently in all phases, alone 
and in combination with chemotherapy or targeted therapeutics for various cancer types 
(Kourie et al., 2016; Wind et al., 2017) (ClinicalTrials.gov). Therefore, BRAFi/MEKi 
combination trials with HER2 inhibitors could be initiated quickly because of the 
substantial pharmacokinetic and pharmacodynamic knowledge of each in patient trials. 
 Historically, loss of PTEN in melanoma cells is associated with PI3K/AKT 
activation and these cells remain dependent on MAPK signaling, rather than PI3K/AKT 
activity for growth. However, our data confirm that BRAF-mutant, PTEN-deficient 
melanomas adaptively shift to a HER3-AKT dependent pathway in response to 
BRAF/MEK inhibitors and this enhances short and long-term growth. Thus, during this 
multitudinal process of BRAF/MEK inhibitor resistance the initial drivers of cell growth 
and survival may no longer be relied upon after the evolution of adaptive drug 
resistance and this has important clinical implications. Treatments must target not only 
oncogenic drivers of melanoma but, adaptive response pathways that modulate 
resistance, HER2/HER3 signaling. Designing triple combination clinical trials using 
BRAF/MEK/HER2 inhibitors may provide a clinical benefit for patients with PTEN-
deficient melanomas and further investigation into the efficacy and tolerability of this 











2. 4 Materials and Methods 
Cell lines 
The human melanoma cell lines used, A375 and SK-MEL-181 have been 
extensively characterized. Cells are routinely tested for mycoplasma contamination by 
DAPI staining and passaged no more than 1 month prior to experiments. Cells were 
cultured in DMEM (A375) or RPMI (SK-MEL-181), supplemented with 5% FBS and 1% 
penicillin–streptomycin.  
RNAi: knock down of PTEN 
Short hairpin RNAs were purchased from Addgene. The pLKO-PTEN-shRNA-
1320 plasmid (plasmid #25638) was used to downregulate PTEN expression. The 
pLKO.1 puro plasmid (plasmid # 8453) was used as non-targeting control. Transfection 
was performed using jetPRIME transfection reagent according to manufacturer’s 
instructions (89129-922, Polyplus Transfection). 
PI3K overexpressing cell lines 
The pLP-LNCX-PIK3CA-WT (Plasmid #25633) and the pLP-LNCX-PIK3CA-
H1047R (Plasmid #25635) plasmids were purchased from Addgene. Plasmids were 
transfected into PLAT-A cells. The supernatant was collected 48 hours later, filtered 
through 45 μm, used to infect A375 cells (with 8 μg/ml polybrene). Two days later, 
polyclonal populations were selected with 250 μg/ml G418. Cells were maintained in 
medium with antibiotics. 
Western blotting 
Melanoma cell lines were lysed in ice-cold multiplexed inhibitor bead (MIB) lysis 
buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 0.5% Triton X-100, 1 mmol/L EDTA, 1 
mmol/L EGTA, pH 7.5) supplemented with complete protease inhibitor cocktail (Roche) 
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and 1% phosphatase inhibitor cocktails 2 and 3 (Sigma) and filtered lysates were boiled 
in 1× SDS sample buffer for 10 minutes at 100°C. Equal amounts of lysate were 
separated by SDS-PAGE, transferred to nitrocellulose membrane, blocked with 5% milk 
in TBS, and subjected to immunoblotting with the following primary antibodies: PTEN, 
phospho-ERK1/2 (218/222), phospho-AKT (S473), phospho-AKT (T308), AKT, 
phospho-HER2 (Y1196), HER2, phospho-HER3 (Y1197), HER3, phospho-P70S6K, and 
P70S6K from Cell Signaling Technology; ERK2 from Santa Cruz Biotechnology.  
Secondary antibodies used were goat anti-rabbit-HRP or goat anti-mouse-HRP from 
Pierce Biotechnology. SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) was used and images were collected on a Bio-Rad ChemiDoc. 
CRISPR deletion of PTEN 
CRISPR/PTEN KO plasmid (sc-400103) and PTEN HDR plasmid (sc-400103-
HDR) were purchased from Santa Cruz. 2 ug of each plasmid was transfected into 
A375 cells and selected with 2.5 ug/ml puromycin for 1 week. Single-cell clones were 
isolated by limiting dilution and screened by western blotting for PTEN. PTEN null 
clones were then infected with Ad-Cre-GFP adenovirus (approximate MOI 30 resulting 
in ~95-99% GFP positive cells) from Vector Biolabs (Cat. No. 1700). 
Immunofluorescent cell staining 
Cells were fixed with 4% paraformaldehyde in Krebs S-buffer for 10 min and 
permeabilized in 0.2% Triton X-100 in PBS for 5 min at room temperature. Cells were 
blocked for 30 min in PBS containing 5% BSA. The primary antibody, diluted to 1:100 in 
PBS containing 5% BSA, was applied for 3h at ambient temperature. This was followed 
by extensive washes in PBS. The fluorescent dye–conjugated secondary antibody and 
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phalloidin dye were diluted to 1:400 in 5% BSA in PBS and applied for 1h at ambient 
temperature followed by extensive washes in PBS. Cells were stained with 0.2µg/ml 
Hoescht 33342 for 10 min at room temperature. The dye was washed out and 
Fluoromount-G (Electron Microscopy Sciences) was used as the mounting medium for 
fixed cells on coverslips. Fluorescent images were acquired on a Zeiss LSM800 
confocal microscope using a 63× objective. The commercial antibody used for 
immunohistochemistry was purchased from Cell Signaling Technology (rabbit anti-
Pten). Alexa Fluor 568 (goat anti–rabbit), Phalloidin (Alexa Fluor 488) and Hoechst 
33342, were purchased from Thermo Fisher Scientific. 
Dose Response Curves 
Dose response curves were performed in 384-well plates. Cells were plated 1 
day prior to first treatment using a BioTek microplate dispenser. The following day cells 
were dosed with drug using a Beckman Coulter Biomek FX instrument. Cells were 
treated with 0.001nM – 100nM Dabrafenib in half log doses, 0.0001nM – 10nM 
Trametinib in half log doses, and the Dabrafenib/Trametinib in combination. For 
screening validation, triple combination dose response curves were performed by 
adding 100nM Neratinib to Dabrafenib/Trametinib combination treatments. DMSO was 
used as a negative control for growth inhibition on each plate. Plates were incubated at 
37°C for 96 hours and lysed by adding 10 µl Cell Titer-Glo reagent (Promega, Cat. No. 
G7570) to 50 µl cell media. Luminescence was measured using a PHERAstar FS 





Cell Line Growth Assays 
The growth assays were performed in 96-well plates. Cells were plated 1 day 
prior to first treatment. For multi-day treatments, media containing fresh drug were 
changed every 3 days unless otherwise noted. Live cells were stained with Hoescht in 
PBS for 20 minutes at 37°C and imaged/counted with a Thermo Cellomics ArrayScan 
VTI at 12 frames per well. 
Crystal Violet Colony Formation Assays 
Crystal violet assays were performed in 6-well plates, with three technical 
replicates per condition. Drug-containing media were changed every 3 days for 2 or 4 
weeks. Cells were rinsed with PBS, fixed in methanol (10 minutes, −20°C), and stained 
with 0.5% crystal violet for 20 minutes. Crystal violet was solubilized with 30% acetic 
acid and quantified by absorbance at 600 nm. 
3D spheroid assay 
A375 Parental, PTEN KO5, and PTEN KO11 cells were plated in low-adhesion 
round-bottom 96 well plates. For spheroids, 5,000 cells were plated per well. Spheroids 
were given 72 hours to form before beginning drug treatment. Before beginning drug 
treatment and at endpoint (7 days) brightfield images was imaged using a Celigo 
instrument. Following imaging, spheroids were lysed in Cell Titer-Glo 3D (Promega, 
Cat. No. G9681) by adding 50 µl reagent to 150 µl cell media. Plates were rotated at 
150 rpm for 30 minutes before luminescence was read using a PHERAstar FS. 
Compounds  
Information on compounds used in screening and subsequent validation 
experiments are listed in Supplementary Table 2S1-2S2. Dabrafenib and Trametinib 
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were purchased from Selleck and dissolved in DMSO. Cultures were treated with 
DMSO as control or with Dabrafenib and Trametinib in combination. 
Epigenetic/Kinase Inhibitor Screening and analysis 
The optimal dose range for Dabrafenib and Trametinib was determined for each 
cell line screened across half log doses. Dabrafenib/Trametinib screens were performed 
in 6x6 dose response matrices. A375 Parental, PTEN KO5, and PTEN KO11 cell lines 
were treated with 3 nM – 1 µM Dabrafenib/Trametinib in half log doses. Cells were 
seeded in 384 well plates using a BioTek microplate dispenser. The following day cells 
were dosed with drug using a Beckman Coulter Biomek FX instrument. The screening 
library was tested for growth inhibition alone or in combination across six doses of the 
screening library: 0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM, and 10 µM. Bortezomib (1 µM) 
was included as a positive control or 0.1% DMSO as a negative control for growth 
inhibition on each plate. Plates were incubated at 37°C for 96 hours and lysed by 
adding 10 µl Cell Titer-Glo reagent (Promega, Cat. No. G7570) to 50 µl cell media. 
Luminescence was measured using a PHERAstar FS instrument and growth inhibition 
was calculated relative to DMSO treated wells.  
Drug synergy analysis 
Drug synergy scores were generated using the SynergyFinder package 1.6.1 
(Ianevski et al., 2017). Bliss scores were calculated without baseline correction and 
using default parameters with the exception that Emin was specified as 0 and Emax as 
100. Synergy was assessed across individual doses of each library compound to 
generate six possible scores per compound. To be considered a hit, a given compound 
had to generate a positive mean synergy score for at least one dose tested in the PTEN 
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KO cell lines screened. Hits were then ranked by the mean of all synergy scores 
produced in the drug combination matrix. Synergy scores represent the percent growth 
inhibition induced by a drug combination which exceeded the expected growth 
inhibition. Expected growth inhibition was calculated based on the effect of each drug as 
a single agent. 
RNA isolation and library preparation 
RNA was isolated from snap frozen cell lines using the RNeasy Plus Mini Kit 
(Qiagen) according to manufacturer's protocol with the optional DNase I treatment 
(Qiagen) for 15 minutes. Two hundred nanograms of total RNA was used as input for 
RNA-seq library construction with a Kapa Stranded mRNA Kit according to the 
manufacturer's protocol. Illumina TruSeq adapter sequences were used for indexing. 
Library amplification was as described with 10 PCR cycles. Equimolar amounts of each 
library were run as multiplexed 1.65 pM pools, single-indexed, on a NextSeq 500–75 
cycle, high output V2 Kit to yield an average of 3.5 × 107 to 4.0 × 107 reads per sample. 
Multiplexed inhibitor bead chromatography and mass spectrometry 
Snap-frozen melanoma cells were lysed in ice-cold MIB lysis buffer (150 mmol/L 
NaCl) as above. Extracts were sonicated 3 × 10 seconds, clarified by centrifugation, and 
syringe-filtered (0.22 μm) prior to Bradford assay quantitation of concentration. Equal 
amounts of total protein (0.3 mg) were gravity-flowed over MIB columns in high salt MIB 
lysis (1 mol/L NaCl). The MIB columns consisted of 175-μL mixture of six type I kinase 
inhibitors (CTx-0294885, VI-16832, PP58, Purvalanol B, UNC-21474, and UNC-8088A) 
custom-synthesized with hydrocarbon linkers and covalently linked to ECH-Sepharose 
(or EAH-Sepharose for Purvalanol B) beads. Columns were washed with 5 mL of high 
 47 
 
salt (1 mol/L NaCl), 5 mL of low salt (150 mmol/L NaCl) MIB lysis buffer, and 0.5 mL 
low-salt lysis buffer with 0.1% SDS. Bound protein was eluted twice with 0.5% SDS, 1% 
β-mercaptoethanol, 100 mmol/L Tris-HCl, pH 6.8 for 15 minutes at 100°C. Eluate was 
treated with DTT (5 mmol/L) for 25 minutes at 60°C and 20 mmol/L iodoacetamide for 
30 minutes in the dark. Following spin concentration using Amicon Ultra-4 (10k cut-off) 
to approximately 100 μL, samples were precipitated by methanol/chloroform, dried in a 
speed-vac and resuspended in 50 mmol/L HEPES (pH 8.0). Tryptic digests were 
performed overnight at 37°C, extracted four times with 1 mL ethyl acetate to remove 
detergent, dried in a speed-vac, and peptides further cleaned using C-18 spin columns 
according to manufacturer's protocol (Pierce). 
Liquid chromatography, mass spectrometry, and analysis 
Peptides were resuspended in 2% ACN and 0.1% formic acid. Forty percent of 
the final peptide suspension was injected onto a Thermo Easy-Spray 75 μm × 25 cm C-
18 column and separated on a 180 minutes gradient (5–40% ACN) using an Easy nLC-
1000. The Thermo Q Exactive mass spectrometry (MS) ESI parameters were as 
follows: 3e6 AGC MS1, 80 milliseconds MS1 max inject time, 1e5 AGC MS2, 100 
milliseconds MS2 max inject time, 20 loop count, 1.8 m/z isolation window, 45 seconds 
dynamic exclusion. Raw files were processed for label-free quantification (LFQ) by 
MaxQuant LFQ using the Uniprot/Swiss-Prot mouse database and default parameters 
were used with the following exceptions—only unique peptides were used, matching 
between runs was utilized, and phospho-STY peptides were included. Normalized LFQ 
intensities were log2-transformed and hierarchical clustering (1−Pearson correlation) 
performed using GENE-E or imported into Perseus software. In Perseus, LFQ 
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intensities were log2-transformed, missing values were imputed from the matrix if at 
least three valid values were present in at least one treatment group, and two-









































2.5 Tables  
 














Trametinib MEK1, MEK2 Type III allosteric  
inhibitor 










Binimetinib MEK1, MEK2 Type III allosteric  
inhibitor 





Neratinib HER2, EGFR Irreversible inhibitor  2017 metastatic and 
early-stage settings 
of HER2+ breast 
cancer 
Afatinib HER2, EGFR Irreversible inhibitor 2013 metastatic NSCLC 
with certain EGFR 














Abbreviations: CLL- Chronic Lymphocytic Leukemia, NSCLC-non-small cell lung cancer  
 
Table 2.1. Targeted kinase inhibitors  
Inhibitors listed in above table are referenced throughout Chapter 1 and 2 and/or used 
throughout the text to assess drug response following PTEN loss. Dabrafenib is a 
reversible ATP-competitive kinase inhibitor that targets BRAF. It is used in combination 
with Trametinib, an allosteric MEK1/2 inhibitor, to abrogate tumor cell growth. This 
combination was FDA-approved in 2014 and is now the standard of care for metastatic 
melanoma patients. Neratinib, an irreversible pan-HER family inhibitor, was identified in 
the synergy screen to synergize with Dabrafenib and Trametinib to block PTEN-loss 


















2.6 Figures  
 
 
Figure 2.1. Knockdown of PTEN in BRAF-mutant melanoma cell lines. 
(A-B) Western blot of PTEN protein in A375 and SKMEL-181 cells showing knock down 
of PTEN expression. PTEN null cells show induction of pAKT. (C-D) Cell viability of 
A375 and SKMEL-181 cells were measured by Hoechst staining after 96 hours 







Figure 2.2. PTEN loss decreases sensitivity of BRAF mutant melanoma cells to 
BRAF/MEK inhibition.  
A) sgRNA-plasmid pool targeting human PTEN was transiently transfected in A375 
cells. Single cell clones were isolated and probed by western blot for PTEN protein. B) 
Western blot of PTEN protein and AKT signaling in A375 Parental, PTEN knockout 5 
(KO5), and PTEN knockout 11 (KO11) cell lines. C) Immunofluorescent staining of 
PTEN protein, actin with Phalloidin, and Hoechst (nuclear marker). D) Dose response 
curves examining BRAFi/MEKi IC50 shift as a result of PTEN loss. E) A375 Parental, 
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KO5, and KO11 growth curves with 100 nM Dabrafenib and 10 nM Trametinib in 
combination. Error bars represent +/- SD, n = 6. P-values comparing Parental drug 
treated vs. PTEN KO cell line drug treated were calculated using two-tailed t-tests, 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001). F)Two-week colony formation assays stained 
with crystal violet and absorbance quantified. Error bars represent +/- SD, n=3. P-values 
comparing Parental drug treated vs. PTEN KO cell line drug treated were calculated 




















Figure 2.3. PTEN loss induces FOXD3 and HER3.  
A) Hierarchical clustering of global transcriptomic changes as a result of PTEN loss. 
PTEN KO5 and KO11 gene expression changes are similar but distinct from 
parental. B) Venn diagram of differentially expressed genes in KO5 and KO11 
cells relative to parental cells with a 2-fold change in expression or greater. 422 
genes are commonly upregulated in both PTEN KO cell lines. C) Long tail plots 
of differentially expressed genes in PTEN KO relative to parental cells. The 
average (KO5 and KO11) log2 fold-change of each gene is plotted. Genes in red 








Figure 2.4. Drug synergy screen against BRAF and MEK in PTEN-null 
melanoma cells.  
A) Schematic for screening approach. Cells were plated in 384 well plates and 
treated 96 hours with 6x6 concentration matrix of library compound in 
combination with Dabrafenib (BRAFi) and Trametinib (MEKi). Cell viability was 
measured with Cell Titer-Glo and drug synergy was measured using the Synergy 
Finder package. B) Synergistic compound rankings using Bliss scoring for 
Dabrafenib/Trametinib screen (performed in KO11 cell line). Synergy scores 
denote the percent inhibition observed following combination treatment which 






Figure 2.5. Transcriptome and kinome analysis of BRAFi/MEKi treated cells. 
A) Venn diagram of differentially expressed genes in KO5 and KO11 cells relative to 
parental cells with a 2-fold change in expression or greater. 939 genes are 
commonly upregulated in both PTEN KO cell lines.  B) Venn diagram of 
differentially expressed genes in KO5 and KO11 cells relative to parental cells 
with a 2-fold change in expression or greater. 1038 genes are commonly 
upregulated in both PTEN KO cell lines. C) HER3, FOXD3, and SOX10 
expression over the course of 7 days BRAFi/MEKi combination therapy. 
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Expression values from STAR and Salmon normalized read counts. D) HER 
family and ligand expression over the course of 7 days BRAFi/MEKi combination 
therapy. Expression values from STAR and Salmon normalized read counts. E) 
Western blot of genes induced in PTEN KO cells following BRAFi/MEKi 
combination treatment and AKT pathway analysis. PTEN KO cells show 
hyperphosphorylation of HER2, HER3, AKT relative to parental cell line. F) MIB-
binding dynamics suggest functional activity of HER3, AKT1, and AKT3 in KO5 






























Figure 2.6. Neratinib synergizes with BRAF/MEK inhibition to suppress 
melanoma growth. 
A) Dose response curves examining BRAFi/MEKi plus Neratinib (triple combination) 
IC50 shift. B) A375 Parental and PTEN KO cells growth curves treated with 10nM 
Dabrafenib/1nM Trametinib in combination, 100nM Neratinib, or triple 
combination. Error bars represent +/- SD, n = 6. P-values comparing 
Dabrafenib/Trametinib vs. triple combination drug treatment were calculated 
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using two-tailed t-tests, (*, P < 0.05; **, P < 0.01; ***, P < 0.001). C) Four-week 
colony formation assays stained with crystal violet and absorbance quantified. 
Error bars represent +/- SD, n=3. P-values comparing Dabrafenib/Trametinib vs. 
triple combination drug treatment were calculated using two-tailed t-tests, 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001). D) 3D spheroids with A375 Parental and 
PTEN KO cell lines treated seven days with 10nM Dabrafenib/1nM Trametinib in 
combination, 100nM Neratinib, or triple combination. Brightfield images were 
taken at 7 days. Cell viability was measured at endpoint with Cell Titer-Glo 3D 
reagent. Error bars show SD, n = 3. P-values were calculated using two-tailed t-














2.7 Supplemental Figures 
 
Supplemental Figure S2.1A CRISPR clones with intact PTEN respond similar 
to Parental cell line 
 
A) Cell viability of A375 Parental and PTEN knockout clones 2 and 6 (PTEN 
expression intact) cells were measured by Hoechst staining after 96 hours 


























Supplemental Figure S2.2 PI3K pathway hyperactivation mimics PTEN loss 
phenotype 
A) A375 flag-tagged PI3K overexpressing (PI3K WT) and PI3KH1047R mutant 
(PI3KH1047R) Star and Salmon read counts for PIK3CA expression. B) Dose-
response relationships of BRAF/ MEK inhibition in PI3K WT and PI3KH1047R. C) 
Western blot of phosphorylated HER3 protein and AKT signaling in PI3K WT and 
PI3KH1047R cells. D) 3D spheroids with A375 PI3K WT and PI3KH1047R cells 
treated seven days with 10nM Dabrafenib/1nM Trametinib in combination, 
300nM Neratinib, or triple combination. Cell viability was measured at endpoint 
with Cell Titer-Glo 3D reagent. Error bars show SD, n = 3. P-values were 









Supplemental Figure S2.3 Pathway Analysis  
(A-B) Up-regulated differentially expressed genes (cut-offs of log2FC ≥1) were used to 
query Enrichr for gene list enrichment analysis. The bar plots for Wiki Pathways 2016 











2.8 Supplemental Tables 
 
 
Supplemental Table S2.1. Screening compound library  
Epigenetic compounds used in synergy screening and subsequent validation 
experiments detailed above. 
Origin CatalogNo. Product Name Targets Class
Selleck Custom Library #2 S1013 Bortezomib Proteosome Other
Selleck Custom Library #2 S1200 Decitabine (5-aza-2'-deoxycytidine) DNMT DNMT
Selleck Custom Library #2 S2170 Givinostat (ITF2357) HDAC HDAC
Selleck Custom Library #2 S7061 GSK126 EZH2 HMT
Selleck Custom Library #2 S7233 Bromosporine pan bromodomain bromodomains
Selleck Custom Library #2 S7610 UNC0631 G9a HMT
In house, on 96well #2 S7152 C646 CBP/p300 HAT domain Acetyl transferase
In house, on 96well #2 Sigma A2385-100MG5-azacytidine DNMT DNMT
In house, on 96well #2 Tocris 5163 A-366 G9a/GLP HMT
In house, on 96well #2 S7281 JIB-04 pan JMJ demethylase KDM
Selleck Custom Library #2 S1045 Trichostatin A (TSA) HDAC HDAC
Selleck Custom Library #2 S1228 Idarubicin HCl Topoisomerase II Topoisomerase
Selleck Custom Library #2 S2244 AR-42 (HDAC-42) HDAC HDAC
Selleck Custom Library #2 S7070 GSK-J4 JMJD3/UTX KDM
Selleck Custom Library #2 S7234 IOX1 pan a-KG oxygenase KDM & oxygenase
Selleck Custom Library #2 S7656 CPI-360 EZH1 HMT
In house, on 96well #2 Sigma SML1525-5MG(-)-JQ1 BRD2/3/4 (inactive control) bromodomains
In house, on 96well #2 S1095 Dacinostat (NVP-LAQ824) HDAC, activates p21 HDAC
In house, on 96well #2 Millipore 531661 AZ505 SMYD2 HMT
In house, on 96well #2 Millipore 420203 Methylstat (JMJD Inhibitor IV) JMJD family KDM
Selleck Custom Library #2 S1069 Luminespib (AUY-922) HSP90 Other
Selleck Custom Library #2 S1231 Topotecan Topoisomerase I Topoisomerase
Selleck Custom Library #2 S2635 CCT128930 AKT2-selective Kinase
Selleck Custom Library #2 S7088 UNC1215 L3MBTL3 Kme reader
Selleck Custom Library #2 S7276 SGI-1027 DNMT DNMT
Selleck Custom Library #2 S7748 EPZ015666 PRMT5 HMT
In house, on 96well #2 S7110 (+)-JQ1 BRD2/3/4 bromodomains
In house, on 96well #2 S1053 Entinostat (MS-275) HDAC HDAC
In house, on 96well #2 Tocris 5365 LLY-507 SMYD2 HMT
In house, on 96well #2 Millipore 219511 KH-CB19 CLK1/4 kinase
Selleck Custom Library #2 S1085 Belinostat HDAC HDAC
Selleck Custom Library #2 S1288 Lactam E ring (Camptothecin (CPT)) Topoisomerase I (inactive control) Topoisomerase
Selleck Custom Library #2 S2779 M344 HDAC HDAC
Selleck Custom Library #2 S7113 Zebularine DNMT DNMT
Selleck Custom Library #2 S7294 PFI-2 SETD7 HMT
Selleck Custom Library #2 S7832 SGC707 PRMT3 HMT
In house, on 96well #2 S2780 I-BET151 BRD2/3/4 bromodomains
In house, on 96well #2 S1541 Ex527 SIRT1/6 HDAC
In house, on 96well #2 S7079 SGC0946 DOT1L HMT
In house, on 96well #2 MedKoo CAT#: 206480PLX7904 BRAF Kinase
Selleck Custom Library #2 S1090 Abexinostat (PCI-24781) HDAC1/3/6/2/11 HDAC
Selleck Custom Library #2 S1422 Droxinostat HDAC8/6 HDAC
Selleck Custom Library #2 S2818 CI994 HDAC1/2/3/8 HDAC
Selleck Custom Library #2 S7164 GSK343 EZH2 HMT
Selleck Custom Library #2 S7315 PFI-3 SMARCA bromodomains
Selleck Custom Library #2 S7906 PFI-4 BRPF1 bromodomains
In house, on 96well #2 Tocris 4891 I-CBP112 CBP/p300 bromodomains
In house, on 96well #2 S1030 LBH-589 (Panobinostat) HDAC HDAC
In house, on 96well #2 Tocris 4343 UNC0638 G9a/GLP HMT
In house, on 96well #2 S1001 ABT-263 (Navitoclax) Bcl-xL Other
Selleck Custom Library #2 S1122 Mocetinostat (MGCD0103) HDAC1/2/11/3 HDAC
Selleck Custom Library #2 S1484 MC1568 HDAC HDAC
Selleck Custom Library #2 S2821 RG108 DNMT DNMT
Selleck Custom Library #2 S7165 UNC1999 EZH2/1 HMT
Selleck Custom Library #2 S7338 AZ191 DYRK1B/A Kinase
Selleck Custom Library #2 S8005 SMI-4a PIM1 Kinase
In house, on 96well #2 OTX015 BRD2/3/4 bromodomains
In house, on 96well #2 S1096 Quisinostat (JNJ-26481585) HDAC1/2/4/10/11 HDAC
In house, on 96well #2 Tocris 5132 UNC0642 G9a/GLP HMT
In house, on 96well #2 Tocris 4299 iCRT 14 beta-catenin/TCF Other
Selleck Custom Library #2 S1141 17-AAG (Tanespimycin) HSP90 Other
Selleck Custom Library #2 S1515 Pracinostat (SB939) HDAC10/3/5/1/4/9/11…6 sparing HDAC
Selleck Custom Library #2 S2919 IOX2 PHD2 oxygenase
Selleck Custom Library #2 S7229 RGFP966 HDAC3 HDAC
Selleck Custom Library #2 S7570 UNC0379 SETD8 HMT
Selleck Custom Library #2 S8049 Tubastatin HDAC6 HDAC
In house, on 96well #2 S7256 SGC-CBP30 CBP/p300 bromodomain bromodomains
In house, on 96well #2 S1047 Vorinostat (SAHA) HDAC HDAC
In house, on 96well #2 Tocris 5057 UNC2327 PRMT3 HMT
In house, on 96well #2 UMI-77 Mcl-1 Other
Selleck Custom Library #2 S1194 CUDC-101 HDAC/EGFR/ERBB2 HDAC
Selleck Custom Library #2 S2012 PCI-34051 HDAC8 HDAC
Selleck Custom Library #2 S3020 Romidepsin (FK228) HDAC1/2 HDAC
Selleck Custom Library #2 S7231 GSK2801 BAZ2B/A bromodomains
Selleck Custom Library #2 S7596 CAY10603 HDAC6 HDAC
Selleck Custom Library #2 S8064 Midostaurin (PKC412) PKCa/g/b/VEGFR2 Kinase
In house, on 96well #2 Tocris 5361 GSK-LSD1 LSD1 demethylase
In house, on 96well #2 S2759 CUCD-907 PI3K/HDAC HDAC + kinase
In house, on 96well #2 Tocris 4905 UNC2400 EZH2 (inactive control for UNC1999) HMT




Supplemental Table S2.2. Screening compound library  
Kinase inhibitors used in synergy screening and subsequent validation experiments 
detailed above. 
Origin CatalogNo. Product Name Targets Class
Selleck Custom Library #1 S1004 Veliparib (ABT-888) PARP Other
Selleck Custom Library #1 S1023 Erlotinib HCl (OSI-744) EGFR Kinase
Selleck Custom Library #1 S1046 Vandetanib (ZD6474) VEGFR, RET Kinase
Selleck Custom Library #1 S1101 Vatalanib (PTK787) 2HCl c-Kit,VEGFR Kinase
Selleck Custom Library #1 S1133 Alisertib (MLN8237) Aurora Kinase Kinase
Selleck Custom Library #1 S1476 SB525334 TGFBR1 Kinase
Selleck Custom Library #1 S2183 BGJ398 (NVP-BGJ398) FGFR Kinase
Selleck Custom Library #1 S2248 CX-4945 (Silmitasertib) CK2 Kinase
Selleck Custom Library #1 S2735 MK-8776 (SCH 900776) Chk1 Kinase
Selleck Custom Library #1 S2924 CHIR-99021 (CT99021) HCl GSK-3 Kinase
Selleck Custom Library #1 S7215 Losmapimod (GW856553X) p38 MAPK Kinase
Selleck Custom Library #1 S1005 Axitinib c-Kit,VEGFR,PDGFR Kinase
Selleck Custom Library #1 S1025 Gefitinib (ZD1839) EGFR Kinase
Selleck Custom Library #1 S1048 VX-680 (Tozasertib, MK-0457) Aurora Kinase Kinase
Selleck Custom Library #1 S1107 Danusertib (PHA-739358) c-RET,FGFR,Bcr-Abl,Aurora Kinase Kinase
Selleck Custom Library #1 S1147 Barasertib (AZD1152-HQPA) Aurora Kinase Kinase
Selleck Custom Library #1 S1525 MK-1775 Wee1 Kinase
Selleck Custom Library #1 S2194 R406 Syk,FLT3 Kinase
Selleck Custom Library #1 S2475 Imatinib (STI571) PDGFR Kinase
Selleck Custom Library #1 S2768 Dinaciclib (SCH727965) CDK1/2/5/9 Kinase
Selleck Custom Library #1 S4901 JNK-IN-8 JNK Kinase
Selleck Custom Library #1 S7270 SRPIN340 SRPK1/2 Kinase
Selleck Custom Library #1 S1006 Saracatinib (AZD0530) Src,Bcr-Abl Kinase
Selleck Custom Library #1 S1026 Imatinib Mesylate (STI571) c-Kit,Bcr-Abl,PDGFR Kinase
Selleck Custom Library #1 S1049 Y-27632 2HCl ROCK Kinase
Selleck Custom Library #1 S1109 BI-2536 PLK/BRD4 Kinase
Selleck Custom Library #1 S1152 PLX-4720 Raf Kinase
Selleck Custom Library #1 S1561 BMS-777607 Axl,c-Met Kinase
Selleck Custom Library #1 S2198 SGI-1776 free base Pim Kinase
Selleck Custom Library #1 S2658 Omipalisib (GSK2126458, GSK458) PI3K/mTOR Kinase
Selleck Custom Library #1 S2783 AZD2014 mTOR Kinase
Selleck Custom Library #1 S7000 AP26113 ALK Kinase
Selleck Custom Library #1 S7320 TG003 CLK1/2/4 Kinase
Selleck Custom Library #1 S1008 Selumetinib (AZD6244) MEK Kinase
Selleck Custom Library #1 S1028 Lapatinib (GW-572016) Ditosylate HER2,EGFR Kinase
Selleck Custom Library #1 S1060 Olaparib (AZD2281, Ku-0059436) PARP Other
Selleck Custom Library #1 S1113 GSK690693 Akt Kinase
Selleck Custom Library #1 S1169 TGX-221 PI3K (p110 beta) Kinase
Selleck Custom Library #1 S1573 Fasudil (HA-1077) HCl ROCK,Autophagy Kinase
Selleck Custom Library #1 S2202 NVP-BHG712 EPHB4 Kinase
Selleck Custom Library #1 S2673 Trametinib (GSK1120212) MEK Kinase
Selleck Custom Library #1 S2789 Tofacitinib (CP-690550,Tasocitinib) JAK Kinase
Selleck Custom Library #1 S7101 SCH772984 ERK Kinase
Selleck Custom Library #1 S7359 K02288 BMPR Kinase
Selleck Custom Library #1 S1010 Nintedanib (BIBF 1120) VEGFR,PDGFR,FGFR Kinase
Selleck Custom Library #1 S1034 NVP-AEW541 IGF-1R Kinase
Selleck Custom Library #1 S1065 GDC-0941 PI3K (pan) Kinase
Selleck Custom Library #1 S1116 Palbociclib (PD-0332991) HCl CDK4/6 Kinase
Selleck Custom Library #1 S1180 XAV-939 beta-catenin (Tankyrase) Other
Selleck Custom Library #1 S1594 Semagacestat (LY450139) Notch (gamma-secretase) Kinase
Selleck Custom Library #1 S2214 AZ 960 JAK Kinase
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Chapter 3: CONCLUSIONS AND FUTURE DIRECTIONS 
 
3.1 Conclusions 
Melanoma is an aggressive cancer that accounts for nearly all skin cancer 
related mortality. The high rate of mortality is largely due to late stage or metastatic 
melanoma, which historically, has been refractive to traditional cytotoxic therapies. 
However, the development of targeted therapeutics in metastatic melanoma, such as 
Dabrafenib and Trametinib in patients with BRAFV600E mutations, have demonstrated 
an improvement in progression free survival, but the response is transient as resistance 
inevitably emerges. Molecular analysis of pre-clinical and clinical samples demonstrated 
changes in gene expression, specifically loss of function mutations in PTEN, that can 
alter the responsiveness of tumors to targeted therapies and subsequently lead to 
resistance. The heterogeneity of melanoma supports the use of personalized medicine 
within the clinic. Thus, understanding the adaptive signaling in response to targeted 
therapy in PTEN-deficient melanoma will ultimately lead to the development of novel 
drug strategies, while also improving existing therapeutic approaches in treating this 
disease.  
This study was set out to dissect the role of PTEN loss in BRAFV600E 
melanoma, specifically the adaptive response to combined BRAF and MEK inhibition 
using RNAseq and chemical proteomics methods to interrogate the functional kinome. 
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It revealed that loss of PTEN activates the PI3K/AKT pathway and alters the dose-
response relationship of dual BRAF/MEK inhibitors by shifting the IC50 and rendering 
cells insensitive to these inhibitors. Further characterization of the PTEN null phenotype 
via transcriptomic analysis revealed a significant induction of HER3 and FOXD3 that 
was amplified by BRAFi/MEKi therapy. Additionally, the lineage transcription factor 
SOX10 was also induced following BRAF/ MEK combination therapy. Furthermore, 
proteomic analysis discovered increased functional activity of HER3 as well as AKT1 
and AKT3 in PTEN-deficient melanomas. This study further aimed to identify novel 
treatment modalities to increase the durability of responses to the current standard of 
care. This is of great importance because of the inevitable emergence of resistance to 
BRAF/MEK inhibition. Using our 175-compound library, I identified inhibitors of HER2 as 
synergistic drug combinations in PTEN knockout cell lines that could abrogate this 
adaptive response. 
The main conclusions are emphasized below and summarized in Figure 3.1. 
PTEN-deficient melanomas adaptively shift to a HER3-AKT dependent pathway in 
response to BRAF/MEK inhibitors and this enhances short and long-term growth. This 
suggests that the initial drivers of cell growth and survival may no longer be relied upon 
after the evolution of adaptive drug resistance. To improve efficacy and make informed 
personalized medicine decisions in the clinic for patients with PTEN-deficient 
melanomas, treatments must target not only oncogenic drivers of melanoma but, 
adaptive response pathways that modulate resistance, HER2/HER3 signaling.  
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In summary, this study offers novel insight into the role of PTEN loss in 
responsiveness to BRAF/MEK inhibition. It contributes to our understanding of early 
adaptive responses to targeted therapy and offers novel treatment strategies to achieve 
durable responses in PTEN-deficient, BRAFV600E melanoma.  
3.2 Future Directions 
The results presented in this thesis identify adaptive signaling mediating the 
resistance to BRAFi/MEKi therapy in PTEN-deficient melanomas. These findings raise a 
number of questions that warrant further investigation.  
3.2.1 Analysis of PTEN loss on adaptive signaling and resistance in long-term 
treatment 
It is known that the timing of initial treatment and duration of therapy can 
influence the adaptive responses to therapy. We and others have shown that SOX10 
expression contributes to resistance to acute BRAFi and BRAFi/MEKi treatment (Han 
et al., 2018). This data is contradictory to a previous report showing that loss of 
SOX10 contributes to BRAFi resistance by activating TGF-β signaling and 
EGFR/PDGFRβ expression (Sun et al., 2014) . However, it should be noted that the 
effect of SOX10 depletion on BRAFi resistance was evaluated at a late time point of 
drug treatment (4 weeks). By contrast, our work focuses on effects of SOX10 
signaling following acute BRAFi/ MEKi treatment (1 and 7 days).  Therefore, the 
differential effects of SOX10 on drug resistance observed are likely due to the 
different roles SOX10 plays at different stages of resistance development. Initially, 
SOX10 may be important for survival by upregulating pro-survival factors such as 
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FOXD3. However, during long-term treatment other adaptive resistance mechanisms 
may be activated and melanoma cells may benefit by loss of SOX10 and subsequent 
activation of growth factor signaling, increased expression of TGF-β and 
EGFR/PDGFRβ.   
The results presented in this thesis demonstrated that SOX10-FOXD3-HER3-
AKT signaling axis may be critical in initial melanoma cell survival on BRAFi/MEKi, and 
although our experiments were performed in a relevant genetic cell model of melanoma; 
still, these studies were performed in vitro following acute BRAFi/MEKi treatment. This 
raises the question: in long-term BRAFi/MEKi treatment, how does PTEN loss influence 
adaptive signaling in vitro and in vivo? Understanding how long-term targeted therapy 
affects adaptive signaling is critical for effectively treating PTEN-deficient melanoma. To 
further interrogate adaptive HER3 signaling in resistance, the efficacy of HER2 
inhibitors to block this resistance, and to ultimately make a difference in clinical settings, 
we need to validate this observation in an animal model. First, I aim to generate 
BRAFi/MEKi resistant cell lines from the A375 parental and PTEN knockout cell lines. I 
will analyze the transcriptomic changes and adaptive kinase signaling using RNAseq 
and MIB/MS. Further probing of transcriptomic changes and kinase signaling unique to 
a PTEN-deficient response in BRAF-mutant melanoma will provide a more complete 
understanding of the adaptive response, which is necessary for the development of 
stable therapies that block resistance. Similar to work done in chapter 2, synergy 
screening will be performed to identify novel treatment modalities that will lead to a 
more durable response. The resistant cell lines will be used to generate xenografts to 
test the efficacy of novel drug combinations. These ideas are represented graphically in 
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Figure 3.2. The completion of these experiments outlined above will begin to confirm 


















Figure 3.1 Graphical representation and model of results.  
Illustrated diagram of key molecular hits that adaptively respond over the course of drug 
treatment. Graphic is based on RNAseq, MIB/MS, and growth response data of PTEN-
deficient BRAF-mutant melanoma at 0, 1, and 7 days treatment with BRAFi/ MEKi. 
PTEN loss activates the PI3K/AKT pathway and alters the dose-response relationship 
of dual BRAF/MEK inhibitors by shifting the IC50 and rendering cells insensitive to these 
inhibitors. Transcriptomic analysis revealed a significant induction of HER3 and FOXD3 
that was amplified by BRAFi/MEKi therapy. The transcription factor SOX10 was also 
induced following BRAF/ MEK combination therapy. Proteomic analysis discovered 
increased functional activity of HER3 as well as AKT1 and AKT3 in PTEN-deficient 
melanomas. Inhibitors of HER2 in combination with BRAFi/MEKi could abrogate this 














Figure 3.2 Long-term BRAFi/MEKi Experiment Overview.  
Graphical representation of the experimental design for long-term treatment and 
molecular analysis of PTEN-deficient BRAF-mutant melanoma response at acute and 
long-term time points on continued treatment with BRAFi/ MEKi compared to no drug 
control. BRAFi/ MEKi resistant cell lines will be generated by continuously culturing 
A375 Parental and PTEN KO cells in low-dose BRAFi/MEKi. Cells will be dose 
escalated as resistant colonies form. Adaptive signaling will be analyzed in resistant 
clones via MIB/MS and RNAseq and compared to results with acute treatment. To 
identify new treatment modalities to overcome adaptive resistance following long term 
treatment, synergy screens will be performed. Using A375 Parental and PTEN KO 
BRAFi/MEKi resistant cell lines, xenografts will be generated to analyze the drug 
response in vivo. Drug combinations using targeted inhibitors identified from the 

































































4. Drug Response in Animal Model
A375 Parental, PTEN KO5, and PTEN KO11 Xenografts
Treat with targeted inhibitors:
Control- no treatment
BRAFi/MEKi
BRAFi/MEKi + acute treatment synergy hit (HER2i)
BRAFi/MEKi + long-term treatment synergy hit
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